Search Results
Feb 09, 2026, 16:15 ET Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the
More news about: Nektar Therapeutics
Jan 30, 2026, 16:10 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and
More news about: Nektar Therapeutics
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 01, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Dec 16, 2025, 07:30 ET REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the
More news about: Nektar Therapeutics
Dec 15, 2025, 18:00 ET Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the
More news about: Nektar Therapeutics
Dec 05, 2025, 18:00 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and
More news about: Nektar Therapeutics
Nov 08, 2025, 17:45 ET New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and
More news about: Nektar Therapeutics
Nov 06, 2025, 16:15 ET Nektar Therapeutics Reports Third Quarter 2025 Financial Results
potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and
More news about: Nektar Therapeutics
Oct 30, 2025, 18:00 ET Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the
More news about: Nektar Therapeutics
Oct 28, 2025, 18:00 ET Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the
More news about: Nektar Therapeutics
Oct 22, 2025, 08:00 ET Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and
More news about: Nektar Therapeutics
Sep 18, 2025, 08:45 ET Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and
More news about: Nektar Therapeutics